Karo Pharma Acquires Nordic OTCs From Teva
Generics giant Teva has divested a portfolio of OTC brands marketed in the Nordics to Sweden's Karo, which has been distributing the products in the region for the past 18 months.
You may also be interested in...
Teva reported a substantial loss in the third quarter after registering a goodwill impairment of $4.6bn, largely linked to legal uncertainties as the firm continues to grapple with price-fixing litigation in the US and its pending opioids settlement.
Karo has picked up the full European rights to the Pevaryl antifungal brand from Johnson & Johnson.
Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.